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A B S T R A C T
Melanin binding affects drug distribution and retention in pigmented ocular tissues, thereby affecting drug
response, duration of activity and toxicity. Therefore, it is a promising possibility for drug targeting and con-
trolled release in the pigmented cells and tissues. Intracellular unbound drug concentrations determine phar-
macological and toxicological actions, but analyses of unbound vs. total drug concentrations in pigmented cells
are lacking. We studied intracellular binding and cellular drug uptake in pigmented retinal pigment epithelial
cells and in non-pigmented ARPE-19 cells with five model drugs (chloroquine, propranolol, timolol, diclofenac,
methotrexate). The unbound drug fractions in pigmented cells were 0.00016–0.73 and in non-pigmented cells
0.017–1.0. Cellular uptake (i.e. distribution ratio Kp), ranged from 1.3 to 6300 in pigmented cells and from 1.0
to 25 in non-pigmented cells. Values for intracellular bioavailability, Fic, were similar in both cells types (al-
though larger variation in pigmented cells). In vitro melanin binding parameters were used to predict in-
tracellular unbound drug fraction and cell uptake. Comparison of predictions with experimental data indicates
that other factors (e.g. ion-trapping, lipophilicity-related binding to other cell components) also play a role.
Melanin binding is a major factor that leads to cellular uptake and unbound drug fractions of a range of 3–4
orders of magnitude indicating that large reservoirs of melanin bound drug can be generated in the cells.
Understanding melanin binding has important implications on retinal drug targeting, efficacy and toxicity.
1. Introduction
Drug-melanin binding is known to accumulate drugs into pigmented
tissues, especially in the eye [1–4]. The eye is the most densely pig-
mented organ in the body [5], and melanin can be found in the anterior
segment in the iris and ciliary body, and in the posterior segment in the
choroid and retinal pigment epithelium (RPE). Melanin binding is a
prevalent phenomenon, as various clinical drugs bind to melanin to
some extent [6]. In the case of ocular drugs, binding has been shown to
modulate drug distribution to the pigmented tissues [7, 8] as well as the
drug response [9]. Systemically administered drugs can also accumu-
late to the pigmented tissues of the eye, a phenomenon demonstrated
most extensively with chloroquine [10, 11]. Therefore, high-binding
drugs can have ocular effects even though the therapeutic target of the
drug is not in the eye. Melanin binding is an important factor to be
considered in ocular as well as other drug therapy and development.
Drug retention in the pigmented tissues has regularly been shown as
elevated total drug concentrations in these tissues, compared to the
corresponding levels in the albino tissues [8, 10–12]. The free, phar-
macologically effective concentrations, especially in the case of high-
binding drugs, may be much lower than the total concentrations [4].
The total concentrations, therefore, are poor indicators for pharmaco-
dynamic drug responses in these tissues. Melanin binding has been
connected, somewhat misleadingly, to drug toxicity in pigmented tis-
sues. Although the binding can accumulate drugs to these tissues, in
fact the free, and not the total concentration in the cells, determines the
toxicity. Melanin can, therefore, also protect the cells from the harmful
drug reactions. Drug toxicity in the pigmented cells depends on the
pharmacodynamic properties of the drug, and it has been shown that
melanin binding itself does not predict ocular toxicity [3].
Although attention has been paid to the unbound drug fractions in
non-pigmented cells and their relation to drug action [13–16], unbound
fractions in pigmented cells have not been investigated. As the differ-
ences between the total and free concentration can be expected to be
higher in pigmented than in non-pigmented cells, it is of high im-
portance to relate the total concentration to the free concentration in
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T
pigmented cells. Melanin binding has been implied as a possible drug
targeting approach, to sustain the action of drugs in pigmented ocular
tissues by a melanin-bound drug depot [12]. To be able to materialize
this approach, it would be of great benefit to understand the relation-
ship of the total and unbound (effective) concentration in these tissues
based on the extent of in vitro melanin binding of targeting drug can-
didates.
We investigated the unbound fraction and the cellular uptake of five
model drugs with varying melanin binding as well as physicochemical
properties, with pigmented primary RPE cells and a non-pigmented RPE
cell line (ARPE-19), to demonstrate the effect of drug-melanin binding
on the intracellular unbound drug fraction as well as cell uptake in
pigmented cells. We also predicted the unbound fractions and cell up-
take with melanin binding parameters to bridge the gap between in vitro
binding to isolated melanin and cell level drug retention.
2. Materials and methods
2.1. Materials
Dimethyl sulfoxide (DMSO) and all of the drug compounds, chlor-
oquine diphosphate salt, diclofenac sodium salt, methotrexate hydrate,
propranolol hydrochloride and timolol maleate salt, were purchased
from Sigma-Aldrich (St. Louis, MO, USA). DMSO was used as a solvent
for the highest concentrations of stock solutions (50mM) of diclofenac,
methotrexate (also 5mM) and timolol. The other stock solutions were
made in Milli-Q water. Dilutions were made in the buffer of choice for
the study, either in Hank's balanced salt solution (HBSS, with CaCl2,
MgCl2) or Dulbecco's phosphate buffered saline (DPBS, without CaCl2,
MgCl2) (Gibco, Thermo Fisher Scientific, Waltham, MA, USA).
2.2. Methods
2.2.1. Isolation of primary RPE cells
The isolation of primary porcine RPE (pRPE) cells was done as
previously reported [17]. Briefly, the extraocular tissues and the ante-
rior part of the eye were removed and the vitreous poured out of the
eye. The eye was filled with DPBS (without CaCl2, MgCl2) and in-
cubated for 10min. The neural retina was carefully removed, the
eyecup was filled with 0.25% trypsin-EDTA (Gibco, Thermo Fisher
Scientific) and incubated at 37 °C for 30–35min. The detached cells
were collected and twice the volume of the cell suspension of growth
medium (10% (v/v) fetal bovine serum, 100 U/ml of penicillin, 100 μg/
ml of streptomycin in DMEM 31885 (Gibco, Thermo Fisher Scientific))
was mixed with the cells. The cells were pelleted three times (once at
450 g for 5min and twice at 200 g for 2min), replacing the supernatant
with fresh growth medium in between and at the end. The cells were
then transferred to a T25 cell culture flask (Sarstedt, Nümbrecht, Ger-
many). Twenty eyes were used for one flask.
2.2.2. Cell culture
ARPE-19 cells (ATCC, Manassas, VA, USA) were cultured in T75 or
T175 cell culture flasks at 37 °C (humidified atmosphere, 7% CO2) using
DMEM/F-12 (Gibco, Thermo Fisher Scientific), supplemented with 10%
(v/v) fetal bovine serum, 100 U/ml of penicillin and 100 μg/ml of
streptomycin, as growth medium. The cells were subcultured once a
week and the growth medium changed once in between. Cell passages
13–26 were used for the studies.
The pRPE cells were grown in the T25 flask for 6–8 days before the
experiments, at 37 °C (humidified atmosphere, 5% CO2). The medium
was changed the day after isolation, and once more before collecting
the cells for experiments.
2.2.3. Intracellular drug binding
For studying intracellular binding of the drugs, a previously de-
scribed method [13, 18] was used with small modifications. The ARPE-
19 cells were collected with TrypLE™ Express (Gibco, Thermo Fisher
Scientific) and the pRPE cells with 0.25% trypsin-EDTA. The cells were
then washed once with DPBS (without CaCl2, MgCl2), counted in a
Bürker chamber, and centrifuged to remove the supernatant. The cell
pellet was stored at −20 °C. Before the experiment, the pellet was
thawed, the cells suspended in HBSS at a density of 10× 106 cells/ml
for ARPE-19 cells and 1×106 cells/ml for pRPE cells, and the cell
suspension homogenized with a tip sonicator (Vibra-Cell Ultrasonic
Liquid Processor VCX500, Sonics, Newtown, CT, USA) for 10 s at 20%
intensity.
The binding was studied in triplicates in rapid equilibrium dialysis
(RED) inserts (Thermo Scientific) with 190 μl of the cell homogenate,
spiked with 10 μl of the compound, in the donor chamber (homogenate
chamber) and 350 μl of HBSS in the receiver chamber (buffer chamber).
Each drug was studied at concentrations 0.5 and 5 μM. The inserts were
incubated at 37 °C with 900-rpm shaking for 5–6 h, depending on the
equilibrium time of each compound (methotrexate 6 h, others 5 h). To
assess the mass balance of the experiment and compound stability, RED
insert controls were used with compound spiked buffer (instead of cell
homogenate) in the donor chamber and well plate controls without the
RED insert with 200 μl of either compound spiked cell homogenate or
compound spiked buffer and 350 μl of HBSS added to the same well.
The mass balance showed recovery values over 88% on all occasions.
After the incubation time, a 40-μl sample was taken from both
chambers, and 40 μl of cell homogenate or HBSS was added to the
buffer and homogenate samples, respectively, to give identical ma-
trices. To these samples, 80 μl of acetonitrile (ACN), 0.2% formic acid
was added to release the drug and precipitate the protein. The samples
were then centrifuged at 15000g for 20min. The supernatant was col-
lected for analysis, the samples from the 5 μM experiments were further
diluted 1:10 with 50:50 [HBSS: (ACN, 0.2% formic acid)]. Internal
standards were added (more in 2.2.7 Analytical methods) to the sam-
ples and the samples stored at −80 °C until analysis.
The unbound fraction inside the cells (fu,cell) was calculated as
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where fu,hom is the unbound fraction in the homogenate, Cbuffer is the
concentration in the buffer chamber and Chom in the homogenate
chamber. D is the dilution factor taking into account the dilution caused
by the in vitro experiment. D was estimated to be 73 for ARPE-19 cells
(10×106 cells/ml, cell diameter 13.8 ± 0.6 μm) and 1100 for pRPE
cells (1× 106 cells/ml, cell diameter 12.0 ± 0.2 μm) assuming a
spherical shape for the cells. Cell diameters were measured with Cedex
XS Cell Analyzer (Roche CustomBiotech, Penzberg, Germany).
2.2.4. Cell uptake and intracellular bioavailability
On the day before the cell uptake experiment, the cells were seeded
on 48-well plates (Nunclon Delta surface, 1.1 cm2/well, Thermo
Scientific) at a density of 100,000 cells/well as described previously
[17]. TrypLE™ Express was used with ARPE-19 cells instead of 0.25%
trypsin-EDTA, and the growth media were the same as mentioned
earlier in 2.2.2 Cell culture. The cells were grown in the wells for
20–24 h before the experiment.
Prior to the experiment, the cells were washed twice with HBSS.
They were then incubated with 250 μl of the drug in HBSS at 37 °C with
175-rpm shaking for 5 h. All drugs were studied in triplicates at the
concentrations 0.5 and 5 μM. After the incubation, the medium (drug
solution above the cells in HBSS) was collected for analysis. The cells
were then washed twice with ice-cold DPBS to remove the drug not
associated with the cells. Subsequently, the cells were frozen at −80 °C
for 2 h, thawed at room temperature for 30min, and lysed with 100 μl
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of Milli-Q water for 10min, and additional 15min with 150 μl of ACN,
0.2% formic acid (together with the Milli-Q water) to release the drug
associated with the cells. The lysate was then collected and centrifuged
at 20000g for 20min. The supernatant was collected for analysis and
internal standards added before storing the samples at −80 °C until
analysis. The 5 μM samples were diluted 1:10 with 40:60 [Milli-Q
water: (ACN, 0.2% formic acid)] prior to the addition of the internal
standards.
The distribution ratio (Kp) describing the cell uptake was calculated





where Acell is the amount in the cell lysate and Cmedium is the con-
centration measured from the medium above the cells.
The intracellular bioavailability (Fic), previously determined by
Mateus et al. [13, 18], was calculated with Eq. 4
= ∗F f Kpic u cell, (4)
2.2.5. Determining the melanin content in the cells
Cellular melanin content in the intracellular drug binding and cell
uptake experiments was determined by spectrophotometry, to ensure a
consistent pigmentation throughout the study and to use the melanin
content values in the predictions of cell uptake and unbound drug
fractions. Equal volumes of cell homogenate and 20% DMSO in 2M
NaOH were mixed. The suspension was then heated at 70 °C for 1 h,
sonicated for 10min and the absorbance measured at 475 nm
(Varioskan LUX™ Multimode microplate reader, Thermo Fisher
Scientific). In the cell uptake experiment, the cells on the 48-well plate
were washed twice with DPBS, subsequently adding 100 μl of Milli-Q
water and 150 μl of 20% DMSO in 2M NaOH in the well and incubating
for 15min. The lysed cells were collected from the well and treated
similarly as the homogenate above.
Isolated porcine ocular melanin from the RPE-choroid (isolation
method previously described [17]) was used as the reference to quan-
titate the melanin content. A 1-mg/ml stock solution of melanin in
DPBS was prepared and treated as described for the cell homogenate
above. It was then diluted to multiple concentrations for the standard
curve. Melanin content of the non-pigmented ARPE-19 cells was also
measured in the same manner, but the absorbance was negligible, and
therefore, the standard curve could be made of melanin only, without
cell material.
2.2.6. Melanin binding studies
Melanin binding of diclofenac and propranolol was determined for
calculating the binding parameters, maximum binding capacity (Bmax),
dissociation constant (Kd), and heterogeneity index (n) for the predic-
tion of cell uptake and intracellular unbound fraction. Melanin binding
was studied with isolated porcine RPE-choroidal melanin with a pre-
viously described method [17] with concentrations 0.5–500 μM of the
drug and 1mg/ml melanin, in DPBS (pH 7.4). For chloroquine, timolol,
and methotrexate, previously reported binding parameters [17]
(pH 7.4) were used. The Sips isotherm was used for the analysis of the
binding parameters [17, 19]. The curve fitting was done in Phoenix
WinNonlin (Certara, Princeton, NJ, USA) with 1/Y2 weighting for
propranolol.
2.2.7. Analytical methods
Samples from the intracellular drug binding and cell uptake ex-
periments were analyzed with an LC-MS/MS technique. Liquid chro-
matography (LC) separations were carried out using Waters Acquity
UPLC (Waters, Massachusetts, USA), Waters Acquity HSS T3 (1.8 μm,
2.1×100mm) column and gradient elution. The solvents used were
0.1% of ACS grade formic acid (Merck, Darmstadt, Germany) in ultra-
pure water (A) and 100% of LC-MS grade ACN (B). More detailed
information of the gradients is presented in Supplementary Table 1. The
flow rate was 0.4 ml/min and the injection volume varied from 0.1 to
1 μl depending of the compound. The column temperature was 26 °C.
For chloroquine, propranolol and timolol, isopropanol injections were
run between every sample to prevent carry-over. With other com-
pounds, blank samples were injected after every third sample to ac-
complish the same.
Mass spectrometric (MS) measurements were carried out using
Waters Xevo triple quadrupole mass spectrometer (TQ-S) equipped with
a Waters electrospray ionization (ESI) source operated in positive ion
mode. The optimal source parameters were compound dependent and
varying; capillary voltage from 2.1 to 3.5 kV, cone voltage from 2 to
45 V, desolvation temperature from 500 to 600 °C and desolvation gas
flow from 900 to 1000 L/h. Source temperature was the same in all
methods, 150 °C, as was the cone gas flow, 150 l/h, and collision gas
flow, 0.15ml/min. Nitrogen was used as the desolvation, nebulizer and
cone gases and argon as the collision gas. Multiple reaction monitoring
(MRM) was used as the scan type. The detailed parameters for each
compound can be found in Supplementary Table 2. The internal stan-
dards were as follows: propranolol for chloroquine and timolol, atenolol
for methotrexate, prednisolone for propranolol, and indomethacin for
diclofenac. Internal standard concentrations in the final sample and
standard solutions ranged from 10 to 100 nM. The resulting data were
analyzed with Waters MassLynx software.
Samples from the melanin binding experiments (propranolol and
diclofenac) were analyzed with UPLC (Acquity UPLC, Waters, Milford,
MA, USA) combined with UV detection (Photodiode Array Detector,
Waters, USA). The separation was carried out on an Ascentis Express
RP-amide (2 μm, 2.1×50mm) column (Supelco, Sigma-Aldrich,
Bellefonte, PA, USA) at 30 °C with an injection volume of 2.5 μl and
flow rate of 0.5ml/min. Both compounds were run on an isocratic
mode with a mobile phase consisting of 15mM phosphate buffer (A)
and ACN (B) (80% A/20% B for propranolol, 45% A/55% B for diclo-
fenac).
The analytical methods were qualified for the purpose. The lower
limits of quantification (LLOQ) for the LC-MS/MS method were as
follows: chloroquine, timolol and propranolol 0.5 nM, methotrexate
1 nM, and diclofenac 5 nM. The LLOQs in the UPLC method were
0.1 μM for propranolol and 0.5 μM for diclofenac. Limit of quantifica-
tion (LOQ) was considered at a signal-to-noise ratio of 9:1.
2.2.8. Predicting intracellular drug binding, cell uptake and intracellular
bioavailability
Cellular uptake and unbound fraction inside the cells were calcu-
lated based on the melanin binding parameters Bmax, Kd, and n. The
fraction inside the cells (fpred) was calculated as reported in [17] with
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where m is the amount of melanin (mg), [L] is the free drug con-
centration (nmol/ml= μM), [L]0 is the original drug concentration in
the medium (μM), Vw is the volume of the medium in the well
(0.25 ml), Vcell is the volume of the cells (ml) (assumed to be
1 μl = 0.001ml), Bcell is the bound drug amount inside the cells (nmol),
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and mcell is the specific measured amount of melanin inside the cells
(mg).



























where the ratio Atotal,cell/Aw (the amount of drug in the medium) can be
expressed as the ratio of the predicted fractions of drug inside (fpred)
and outside (1-fpred) the cells. The ratio Vw/Vcell equals to 250.
Fic values were predicted (Fic,pred) based on the pH partitioning
theory as presented in [13]. The pKa values presented in Table 1 were
used, and the pH values assumed for melanosomes and lysosomes were
5.0, cytosol 7.1, and medium outside the cells 7.4. The volume of ly-
sosomes was assumed to be 1% of the total cell volume and the volume
of melanosomes 7% of the cell volume [20].
Based on Fic,pred, Kp values were predicted (Kppred) with Eq. 10,
taking into account both the melanin binding (in fu,cell,pred) and pH
partitioning in the subcellular compartments (in Fic,pred).
=Kp F f/pred ic pred u cell pred, , , (10)
3. Results
3.1. Melanin binding
Melanin binding was studied with propranolol and diclofenac
(Table 2). Melanin binding of diclofenac could not be detected in the
experimental conditions (0.5–500 μM drug, 1mg/ml melanin, pH 7.4)
and the binding parameters could not be calculated. Propranolol
binding parameters are reported in Table 2. Melanin binding of the
other drugs, chloroquine, timolol and methotrexate, has been studied
previously [17] and these parameters were used here (Table 2). From
here on, chloroquine, propranolol, and timolol, will be called melanin
binders and diclofenac and methotrexate low/non-binders (although
their binding was not detectable in the conditions of this study, they
have low binding levels in other conditions [6, 17]).
3.2. Intracellular drug binding, cell uptake and intracellular bioavailability
The intracellular unbound drug fraction ranged from 0.00016 to
0.73 in the pigmented pRPE cells and from 0.017 to 1.0 in the non-
pigmented ARPE-19 cells (Fig. 1A). It was clear that melanin binding
decreased the unbound fraction, as the melanin-binding drugs, chlor-
oquine, propranolol, and timolol, had 10–300-fold lower unbound
fractions in pigmented cells, whereas the low/non-binders, metho-
trexate and diclofenac, showed 0–10-fold lower unbound fractions.
Cell uptake values showed clear differences between drugs and
pigmented vs. non-pigmented cells: Kp was 1.3–6300 in pRPE cells and
1.0–25 in ARPE-19 cells (Fig. 1B). Melanin binders had again much
higher uptake to the pigmented than the non-pigmented cells, with
30–270-fold differences. The uptake of the low/non-binders was similar
in both cell types. Chloroquine uptake was much lower than expected,
based on the extent of melanin binding, as well as our previous cell
uptake results of chloroquine [17]. Possible reasons for this are dis-
cussed later.
The Fic values ranged from 0.28–2.2 in the non-pigmented cells and
from 0.04 to 8.2 in the pigmented cells (Fig. 1C). In theory, the in-
tracellular bioavailability (Fic) is expected to be 1 for passively diffusing
drugs and above 1 for positively charged drugs that get trapped in
acidic intracellular compartments (ion trapping) such as lysosomes and
melanosomes. Melanin binding, or other cellular binding, should not
affect the Fic, as the extent of binding-related cell uptake is compen-
sated by the lowering of the unbound fraction. On average, the Fic was
lower for the acidic compounds than the basic compounds (Table 3), as
can be expected due to ion trapping.
3.3. Predicted intracellular unbound fraction, cell uptake and intracellular
bioavailability
The unbound drug fractions inside the pigmented cells were pre-
dicted based on the melanin binding parameters in Table 2. The mea-
sured melanin amount inside the cells, 25.4 ± 1.2 μg/well (mean ±
SD), was used in the predictions. The predicted unbound fractions of
the melanin binders were approximately 10-fold higher than the mea-
sured values (Fig. 2A). For the low/non-binding drugs, the predicted
value was 1 (as they do not bind to melanin, which is the only pre-
dicting factor in this case). This was close to the measured value for
methotrexate (0.7) but 100-fold higher than the measured value for
diclofenac (0.01). As other cellular binding also affects the unbound
fraction, the lower measured unbound fraction of diclofenac can be
explained by its lipophilicity. The correlation coefficient of the pre-
dicted and measured values was 0.73 (log-log plot) (Supplementary
Fig. 1), and it is clear that lipophilicity and binding to other cell com-
ponents, especially in the case of low/non-melanin-binding drugs,
should be accounted for when assessing the unbound fraction.
Cell uptake to the pigmented cells was also predicted with the
melanin binding parameters. The predicted uptake (Kppred,mel) was
10–100-fold lower than the measured values for the basic drugs, pro-
pranolol and timolol (melanin binders) (Fig. 2B). Chloroquine was an
outlier here (because of the measured low cell uptake), and the pre-
dicted value was similar to the measured value. The predicted value
should be lower than the measured value for all basic drugs, as pH
partitioning to the subcellular acidic compartments (melanosomes, ly-
sosomes) as well as other cellular binding increase the uptake. For the
acidic low/non-binders, the melanin-binding-predicted Kp values
Table 1
The acid/base status, pKa and logD7.4 values for the studied drugs (ACD pre-
dicted [21]).
Drug pKa,base pKa,acid logD7.4
Chloroquine 10.4 – 1.6
Propranolol 9.5 – 0.8
Timolol 9.4 – −0.6
Diclofenac – 4.2 1.4
Methotrexate – 3.5 −5.1
Table 2
Melanin binding parameters (mean ± SEM) for the studied drugs from left to right in the decreasing order of melanin binding.
Parameter Chloroquinea Propranolol Timolola Diclofenac Methotrexatea
Bmax (nmol/mg) 380 ± 40 176 ± 60 39 ± 6 – –
Kd (μM) 76 ± 23 163 ± 100 120 ± 30 – –
n 0.61 ± 0.01 0.89 ± 0.05 0.95 ± 0.03 – –
% bound at 1 μM 99.6 70 32 0 0
a [17]
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compared to the measured values similarly as in predicting the un-
bound fraction. Kppred,mel for methotrexate was similar than the mea-
sured Kp, but for diclofenac, the predicted value was 10-fold lower.
This, again, can be explained by the lipophilicity of the drug causing
binding to other cellular components than melanin. The correlation
coefficient between the measured and melanin-binding-predicted
values (0.5 μM study concentration) on a log-log plot was 0.64 (Sup-
plementary Fig. 2). Cell uptake was also predicted taking into account
the pH partitioning (Fig. 3) in the subcellular compartments in addition
to melanin binding (Kppred) (Fig. 2B). This improved the log-log cor-
relation to the measured values from 0.64 to 0.79 (Supplementary
Fig. 2).
The Fic values in both cell types were predicted according to pH
partitioning to different subcellular compartments (cytosol, lysosomes,
melanosomes) (Fig. 3) based on the pKa values of the drugs studied
(Table 1). The measured values for the basic drugs were lower in both
cells than the predicted values, but for the acidic drugs the measured
and the predicted values were similar (Table 3). The differences in the
measured and predicted values were comparable to a previous study
[13], where a much wider group of drugs was studied with non-pig-
mented cells. The difference in the predicted values in different cell
types arises from the volume difference of the pH 5.0 compartments
(only lysosomes in ARPE-19 cells vs. lysosomes and melanosomes in
pRPE cells).
Fig. 1. Measured values in pRPE (left) and ARPE-19 cells (right), A: intracellular unbound fractions (fu,cell), B: cell uptake (Kp), C: intracellular bioavailability (Fic).
The error bars describe the standard error of mean (SEM), and are in some cases encompassed by the symbol.
Table 3
Predicted and measured Fic (mean ± SEM) grouped by the acid/base status of
the drug.
Fic,pred Fic,measured
Basic pRPE 22 ± 0.1 2.7 ± 1.2
ARPE-19 4.5 ± 0.02 1.3 ± 0.3
Acidic pRPE 0.46a 0.50 ± 0.3b
ARPE-19 0.50a 0.44 ± 0.1b
a Mean and SEM not calculated, as there were only two data points for the
predicted values. Both data points had values rounding up to the presented
value.
b Mean and SEM calculated of the individual four data points (two drugs
with two concentrations).
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4. Discussion
To obtain targeted and sustained drug action through melanin
binding, a key aspect is the capability of the free concentration to
produce a sustained drug response without causing toxicity. As in-
tracellular unbound drug fraction represents the effective fraction of the
drug inside the cells, it is a more important factor than the total con-
centration in understanding the pharmacodynamic effect of the drug.
We measured intracellular unbound drug fractions and cell uptake of
five model drugs with different melanin binding (Table 2) and physi-
cochemical (Table 1) properties comparing pigmented and non-
pigmented RPE cells.
The intracellular unbound fractions were lower in pigmented than
non-pigmented cells for all of the drugs except for methotrexate.
Methotrexate had similar unbound fraction, close to 1, in both cell
types, as can be expected since it is a low- or non-melanin-binding,
hydrophilic drug. The unbound fraction of diclofenac, also a low/non-
binding drug, was up to 10-fold lower, and the unbound fractions of the
melanin-binding drugs, timolol, propranolol, and chloroquine, 10–300-
fold lower in pigmented than non-pigmented cells. The lowering of the
unbound fraction did not directly correlate with the extent of in vitro
melanin binding (isolated porcine RPE-choroidal melanin), but due to
the interplay of other cellular binding together with melanin binding
and the low number of compounds studied, it is difficult to obtain
comprehensive correlations and specify reasons. Nevertheless, the rank
order of the unbound fractions was in the order of melanin binding,
except for the lipophilic diclofenac which had similar unbound fraction
than the moderately melanin-binding timolol. Therefore, it can be
concluded that melanin binding plays an important role in determining
the unbound fraction, but other cellular binding events also contribute.
The cell uptake of the melanin-binding drugs was much higher
(30–270-fold) in pigmented than non-pigmented cells. The uptake of
the low/non-binders was similar in both cells, thus, correlating with the
result of low/non-existent in vitro melanin binding. Therefore, we can
say that melanin binding increased the drug uptake considerably.
Surprisingly, propranolol had the highest uptake in the pigmented cells.
Chloroquine, the highest melanin binder, would have been expected to
have higher uptake than propranolol, due to the extensive melanin
binding, as they had similar uptake in the non-pigmented cells. In our
Fig. 2. Predicted vs. measured values, A: intracellular unbound fractions (fu,cell,pred), B: cell uptake (Kppred,mel and Kppred). The error bars describe SEM (there are no
error bars in the predicted values).
Fig. 3. pH partitioning inside the pigmented and non-pigmented cells. Non-
pigmented cells were assumed not to have melanosomes.
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previous experiments [17], chloroquine had much higher uptake in
primary cells from the same source as in this study (Kp ~1000 here vs.
25,000 in [17]), adding to the unexpectedness of the low uptake here.
The uptake of timolol, however, was similar in both studies (here and in
[17]), therefore, other than melanin binding effects can be debated to
cause the incoherence of chloroquine results. As an example, chlor-
oquine is an MRP-1 efflux transporter substrate [22, 23]. RPE cells have
been determined to express efflux transporters, such as MRP-1, -4, and
-5 [24], and a high expression of the right efflux transporter could
explain the differences. Timolol is a P-gp substrate but has not been
reported to be a substrate for the above MRPs, therefore, allowing for
different efflux outcomes for chloroquine and timolol. Other factors,
such as differences in intramelanosomal pH (which is not known), can
also participate in the differences. Chloroquine is, for example, known
to increase the pH of lysosomes. A similar pH change may take place in
melanosomes, thereby affecting the pH partitioning of chloroquine and
causing variation in drug uptake. Nevertheless, the correlation between
measured and predicted uptake values was improved (Supplementary
Fig. 2, more information later) when chloroquine uptake results from
this study were replaced with the higher uptake results from [17].
Therefore, it is safe to say that chloroquine uptake was an outlier in this
study with a much lower than expected uptake into pigmented cells, as
for the other drugs, melanin binding could explain the extent of uptake.
It is clear that more drugs need to be studied to make more reliable
conclusions and to reduce the effect of outliers on the outcome.
The unbound fraction and cell uptake in the non-pigmented ARPE-
19 cells were similar as reported before with non-pigmented HEK293
cells for diclofenac and propranolol (compounds for which literature
references could be found) [13]. Mateus et al. [18] have reported 10-
fold lower unbound fractions for these drugs in MDCK cells (non-pig-
mented) than in HEK293 cells, corresponding with our result for the
low/non-melanin-binder diclofenac in pigmented pRPE cells. As re-
ported before by Mateus et al. [18] and others [25], the binding to non-
pigmented cellular components is not dependent on the cell type, and is
mainly governed by membrane partitioning of the compound. Although
individual compounds may have some differences in different cell
types, a correlation of unbound fractions in different cell types with a
larger set of compounds has been seen. Our results are in accordance
with this finding, as no higher than 10-fold differences were found for
the low/non-melanin binders in the two cell types studied here.
We predicted the intracellular unbound drug fractions based on
melanin binding parameters from in vitro binding studies. The predicted
fractions were 10-fold higher than the measured values for the melanin-
binding drugs. Of the low/non-binders, methotrexate had similar pre-
dicted and measured unbound fractions, but the predicted unbound
fraction of diclofenac was 100-fold higher than the measured value. As
other cellular binding than melanin binding affects the unbound frac-
tion, it is clear that the whole unbound fraction cannot be predicted
with only melanin binding (correlation on a log-log plot 0.73). Melanin
binding could, however, predict the rank order of the melanin-binding
drugs, and all the drugs except for diclofenac, and is a relevant pre-
dictor of the quantity of the unbound fraction. Nevertheless, experi-
ments with more compounds are needed to make more detailed con-
clusions and correlations of the unbound fraction in pigmented cells
with melanin binding as well as other parameters of the drug, such as
lipophilicity, affecting the binding to other, non-melanosomal cell
components.
Cell uptake was predicted with the melanin binding parameters and,
additionally, considering both melanin binding and intracellular pH
partitioning of the drug. Melanin binding explained the uptake partly
(log-log plot correlation coefficient 0.64), but adding pH partitioning to
the model, improved the correlation (0.79). Interestingly, when repla-
cing the chloroquine uptake results of this study (outlier) with the much
higher uptake results from our previous study [17] with a similar study
setting, a clear improvement in the correlation of the predicted values
was seen (Supplementary Fig. 3). The melanin-binding predicted cell
uptake (Kppred,mel) correlation with the measured Kp values improved
from 0.64 to 0.88 and the melanin-binding and pH partitioning pre-
dicted cell uptake (Kppred) correlation improved from 0.79 to 0.94.
Positively charged drugs tend to get trapped inside the acidic in-
tracellular compartments, as the charged form does not penetrate the
membranes as well as the neutral form. If melanosomes have an acidic
intracellular pH, they increase the intracellular acidic compartment
volume compared to non-pigmented cells that do not have melano-
somes. The estimated area that melanin occupies in the RPE cell has
been evaluated to be 7% [20]. Detailed information of melanosomal
volume excluding the volume of melanin and information of lysosomal
volumes of different cells is needed to assess the effect more precisely.
Here, we assumed a melanosomal volume of 7% of the total cell volume
for the pigmented cells and a lysosomal volume of 1% of the cell vo-
lume for both cell types. These volume differences caused a 4-fold
higher predicted intracellular bioavailability for the basic drugs in
pigmented, melanosome containing cells (Table 3). Therefore, ion
trapping into melanosomes can increase the uptake to pigmented cells
of even low-binding basic drugs compared to the uptake to non-pig-
mented cells. All in all, however, many factors affect this relationship
and more information is required for a thorough understanding of in-
tracellular distribution with and without melanin binding.
Although a convenient method to measure unbound intracellular
drug fractions, the method used here does not take into account all the
physiological factors regarding melanin binding. Melanosomal pH may
play a role in the binding of drugs, a factor that cannot be considered
with this method. Methotrexate, as an example, has been found to bind
to melanin at pH values 4.8 and 5.0, although it does not bind at pH 7.4
[17, 26]. In the experimental conditions of this study, the melanin is
expected to be in the pH environment of the in vitro setting (pH 7.4), as
the homogenization method is expected to break the melanosomal
membrane. Therefore, melanin binding of methotrexate is not expected
to take place in these conditions. The pH inside melanosomes can be
expected to be less than 7.4, but the exact pH of ocular melanosomes
has not been determined [4]. Without a measured value for the in-
tramelanosomal pH, the correct pH at which to study melanin binding
in vitro, remains unknown. Therefore, definite conclusions cannot be
made of the importance of in vitro melanin binding of methotrexate, or
other compounds, at an acidic pH. Taking intramelanosomal pH into
account is difficult with any other method than studying live whole
cells. Estimation of the pH from isolated melanosomes, for example, is
problematic, as fluorescent probes are generally used for pH determi-
nation, and melanin absorbs light of a wide range of wave lengths.
Determining the unbound fractions from whole cells, on the other hand,
is relatively challenging due to the requirement of separating the free
and bound drug. Therefore, the cell homogenate binding used here is a
relevant method. The benefit of this method is that it takes into account
other cellular binding together with melanin binding, therefore, giving
much better estimates of the unbound fraction inside the cells than in
vitro studies with melanin alone.
As the isolation of primary RPE cells is somewhat laborious, a better
source for melanin-containing cells with reproducible melanin levels
comparable to in vivo tissue melanin content, would improve the sig-
nificance of the method used here. Adult primary RPE cells do not
synthesize melanin, and the melanin concentration is, therefore, diluted
during cell division. Melanin-loaded ARPE-19 cells [27], melanin-syn-
thesizing primary human fetal RPE cells [28] or highly pigmented stem-
cell derived RPE cells [29] could be viable options to be used with this
method, but have not been characterized or validated for this purpose.
A more continuous cell source would also increase the throughput of
this method, benefiting for example industrial screening approaches.
As emphasized before, the free drug concentration inside the cells is
a more important parameter compared to the total concentration of the
drug when considering the action of the drug. The distribution of drugs
to pigmented tissues does not yet tell much about the effect in these
tissues, as the unbound concentration of a melanin-binding drug, as
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shown in this study, is much lower than the total concentration. To
obtain sustained action of the drug in pigmented ocular tissues through
a melanin-bound drug depot, assessing the unbound fraction is of high
importance. This targeting approach has already been shown as a
possibility in treating choroidal neovascularization in pigmented rats
and mice [12]. The improved action was shown as elevated total drug
concentrations of a high melanin binder in the pigmented uveal tract in
rats. The effect of the drug was confirmed separately in pigmented
mice, and the studied drug candidate was concluded to be more ef-
fective than the control drug due to higher distribution of the drug
candidate into pigmented tissues caused by its higher melanin binding.
Here, the total distribution of the drug to the pigmented tissues corre-
sponded with short-term efficacy of the drug but long-term corre-
spondence still remains unknown. Measuring unbound drug fractions in
pigmented cells bridges the gap between drug distribution and drug
effect in pigmented tissues, as more information can be obtained from
the total concentration when understanding its relationship with the
free concentration.
5. Conclusions
We demonstrated the decreased intracellular unbound fractions and
increased cell uptake of melanin-binding drugs in pigmented compared
to non-pigmented RPE cells. We also predicted cell uptake and unbound
fractions based on melanin binding parameters from in vitro binding
studies. The correlation between predicted and measured cell uptake
demonstrated the suitability of using in vitro melanin binding para-
meters in predicting drug uptake, but other factors, such as pH parti-
tioning inside the cells, can improve the prediction. A correlation was
also found between the measured and predicted intracellular unbound
fractions, but here other cellular binding seems to play an important
role, and should be taken into account. All in all, our results show a
wide range of values (3–4 orders of magnitude) for cellular uptake and
unbound fraction in the pigmented RPE cells. The cell uptake and free
concentration values indicate that melanin bound drug can form a
major intracellular depot for long-term drug release within the pig-
mented cells. Understanding the relationship of the free and total drug
concentration can help bridge the gap between drug distribution and
drug action in pigmented tissues. This is important in understanding the
implications of pigment binding for targeting, efficacy and toxicity of
drugs.
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